Bioniche Life Sciences Inc. has received notice from the USDA that E. coli O157:H7 cattle vaccine is eligible for a conditional license.
Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company. The United States Department of Agriculture (USDA) announced that the latest data for its E. coli O157:H7 cattle vaccine “meets the ‘expectation of efficacy’ standard” and is eligible for a conditional license, providing that the Company develops a plan that would collect sufficient data to move the product to full licensure.
The conditional license, when granted, will provide the company full access to the U.S. market with two restrictions: At least one step in the manufacturing process must be performed in the United States and Bioniche will not be permitted to use a trademark name for the vaccine.
The Bioniche vaccine is the world’s first vaccine that may be used as an on-farm intervention to reduce the amount of E. coli O157:H7 shed by cattle.
Bioniche and its collaborators have been moving the vaccine towards commercial availability for eight years and it has been extensively tested at the University Nebraska-Lincoln, with efficacy results now being published in peer-reviewed scientific journals, most recently, the Journal of Food Protection, in November, 2007.
Source: American Meat Institute (AMI)